Aigen Investment Management LP Acquires New Holdings in DexCom, Inc. (NASDAQ:DXCM)

Aigen Investment Management LP acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,211 shares of the medical device company’s stock, valued at approximately $349,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Capital Insight Partners LLC lifted its position in DexCom by 2.5% during the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after purchasing an additional 90 shares during the period. HM Payson & Co. lifted its position in DexCom by 6.0% during the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after purchasing an additional 100 shares during the period. Clear Creek Financial Management LLC raised its position in DexCom by 4.2% in the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after acquiring an additional 120 shares during the period. SeaCrest Wealth Management LLC raised its position in DexCom by 3.6% in the second quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock worth $501,000 after acquiring an additional 152 shares during the period. Finally, Securian Asset Management Inc. raised its position in DexCom by 0.7% in the second quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock worth $2,593,000 after acquiring an additional 161 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $75.88 on Friday. The firm has a fifty day simple moving average of $69.89 and a two-hundred day simple moving average of $92.01. The stock has a market capitalization of $29.64 billion, a P/E ratio of 45.44, a PEG ratio of 2.22 and a beta of 1.17. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

Wall Street Analyst Weigh In

Several research firms have weighed in on DXCM. BTIG Research decreased their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. UBS Group decreased their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Raymond James decreased their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $104.59.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.